Diabetes: Artificial Pancreas
The following is an extract from the Adjournment debate entitled Diabetes: Artificial Pancreas on 12 December 2018.
As the right hon. Gentleman said, artificial pancreas devices are an emerging technology that combines continuous glucose monitoring with insulin pumps. One system, the Medtronic 670G system, which he mentioned, was recently approved by the US Food and Drug Administration and a European licence is being pursued.
[Official Report, 12 December 2018, Vol. 651, c. 361.]
Letter of correction from the Minister for Care:
An error has been identified in the response I gave to the right hon. Member for Knowsley (Mr Howarth) in the debate entitled Diabetes: Artificial Pancreas.
The correct response should have been:
As the right hon. Gentleman said, artificial pancreas devices are an emerging technology that combines continuous glucose monitoring with insulin pumps. One system, the Medtronic 670G hybrid closed loop system, which he mentioned, was approved by the US Food and Drug Administration in 2016 and received a Conformité Européenne mark in June 2018.”